235 related articles for article (PubMed ID: 34898007)
1. Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population-based observational study.
Fang W; Huang Y; Han X; Peng J; Zheng M
Cancer Med; 2022 Feb; 11(3):764-777. PubMed ID: 34898007
[TBL] [Abstract][Full Text] [Related]
2. The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups.
Zheng H; Ge C; Lin H; Zhou S; Tang W; Wang Q; Zhang X; Jin X; Xu X; Du J; Fu J
PLoS One; 2023; 18(1):e0280474. PubMed ID: 36652446
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
4. Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer.
Fu J; Wu L; Jiang M; Li D; Jiang T; Fu W; Wang L; Du J
Cancer; 2017 Jul; 123(13):2432-2443. PubMed ID: 28267199
[TBL] [Abstract][Full Text] [Related]
5. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
6. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer.
Wang Z; Wang H; Ding X; Chen X; Shen K
Ther Adv Med Oncol; 2020; 12():1758835920932674. PubMed ID: 32550867
[TBL] [Abstract][Full Text] [Related]
7. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
9. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study.
Gong Y; Liu YR; Ji P; Hu X; Shao ZM
Sci Rep; 2017 Mar; 7():45411. PubMed ID: 28345619
[TBL] [Abstract][Full Text] [Related]
10. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
11. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
[TBL] [Abstract][Full Text] [Related]
12. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
[TBL] [Abstract][Full Text] [Related]
13. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
14. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
Wu Q; Li J; Zhu S; Wu J; Chen C; Liu Q; Wei W; Zhang Y; Sun S
Oncotarget; 2017 Apr; 8(17):27990-27996. PubMed ID: 28427196
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
17. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
[TBL] [Abstract][Full Text] [Related]
18. Histologic heterogeneity predicts patient prognosis of HER2-positive metastatic breast cancer: A retrospective study based on SEER database.
Wang Y; Liang Y; Ye F; Luo D; Jin Y; Li Y; Zhao W; Chen B; Wang L; Yang Q
Cancer Med; 2023 Sep; 12(18):18597-18610. PubMed ID: 37605516
[TBL] [Abstract][Full Text] [Related]
19. Tumor subtypes and survival in male breast cancer.
Leone J; Freedman RA; Lin NU; Tolaney SM; Vallejo CT; Leone BA; Winer EP; Leone JP
Breast Cancer Res Treat; 2021 Aug; 188(3):695-702. PubMed ID: 33770314
[TBL] [Abstract][Full Text] [Related]
20. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
